PD-1/PD-L1 inhibitors combined with chemotherapy in the treatment of thymic carcinoma metastasis to the liver Case Report Journal of Clinical Images and Medical Case Reports

but pa clitaxel + carboplatin is the first choice for the first-line chemo therapy of thymic carcinoma, and fluorouracil/tetrahydrofolate, gemcitabine/capecitabine, paclitaxel, pemetreuse, etoposide, isophoramide and so on, can be selected for the second-line chemotherapy [3]. There is a lack of effective evidence-based medical evidence for targeted therapy of thymic carcinoma, but the new drugs in the study include everolimus, sunitinib and Abstract Epithelial neoplasms of the thymus is a relatively rare malignancy. In this report, we present a case of thymic carcinoma of a 68-year-old man with hepatic metastasis, which with the severe hypokalemia, hypoproteinemia, and fatigue of concomitant symptom. After positive symptomatic treatment such as correction of electrolyte disorder, sup plementation of albumin and nutritional support, the patient’s general condition recovered and improved. Then, we reviewed the literature on the treatment of thymic carcinoma, and decided to use immunotherapy combined with chemotherapy to treat this case of advanced thymic squamous carcinoma, expecting to have a good efficacy and improve the progression-free and overall survival.